Gut mucosal colonisation with extended-spectrum beta-lactamase producing Enterobacteriaceae in sub-Saharan Africa: a systematic review and meta-analysis [version 1; peer review: 2 approved]

Background: Extended-spectrum beta-lactamase producing Enterobacteriaceae (ESBL-E) threaten human health; and, in areas of sub-Saharan Africa (sSA) where carbapenems are not available, may render ESBL-E infections untreatable. Gut mucosal colonisation probably occurs before infection, making prevent...

Full description

Bibliographic Details
Main Authors: Joseph M. Lewis, Rebecca Lester, Paul Garner, Nicholas A. Feasey
Format: Article
Language:English
Published: Wellcome 2019-10-01
Series:Wellcome Open Research
Online Access:https://wellcomeopenresearch.org/articles/4-160/v1
id doaj-974574f43a034906a5b17a905605ce6a
record_format Article
spelling doaj-974574f43a034906a5b17a905605ce6a2020-11-25T01:57:05ZengWellcomeWellcome Open Research2398-502X2019-10-01410.12688/wellcomeopenres.15514.116981Gut mucosal colonisation with extended-spectrum beta-lactamase producing Enterobacteriaceae in sub-Saharan Africa: a systematic review and meta-analysis [version 1; peer review: 2 approved]Joseph M. Lewis0Rebecca Lester1Paul Garner2Nicholas A. Feasey3Liverpool School of Tropical Medicine, Liverpool, Merseyside, L3 5QA, UKLiverpool School of Tropical Medicine, Liverpool, Merseyside, L3 5QA, UKLiverpool School of Tropical Medicine, Liverpool, Merseyside, L3 5QA, UKLiverpool School of Tropical Medicine, Liverpool, Merseyside, L3 5QA, UKBackground: Extended-spectrum beta-lactamase producing Enterobacteriaceae (ESBL-E) threaten human health; and, in areas of sub-Saharan Africa (sSA) where carbapenems are not available, may render ESBL-E infections untreatable. Gut mucosal colonisation probably occurs before infection, making prevention of colonisation an attractive target for intervention, but the epidemiology of ESBL-E in sSA is poorly described. Objectives: Describe ESBL-E colonisation prevalence in sSA and risk factors associated with colonisation. Methods: Studies included were prospective cross-sectional or cohort studies reporting gut mucosal ESBL-E colonisation in any population in sSA. We searched PubMed and Scopus on 18 December 2018. We summarise the range of prevalence across sites and tabulated risk factors for colonisation. The protocol was registered (Prospero ID CRD42019123559). Results: From 2975 abstracts we identified 32 studies including a total of 8619 participants from a range of countries and settings. Six studies were longitudinal; no longitudinal studies followed patients beyond hospital discharge.  Prevalence varied between 5 and 84% with a median of 31%, with a relationship to setting: pooled ESBL-E colonisation in community studies was 18% (95% CI 12 to 28, 12 studies); in studies recruiting people at admission to hospital colonisation was 32% (95% CI 24 to 41% 8 studies); and for inpatients, colonisation was 55% (95% CI 49 to 60%, 7 studies). Antimicrobial use was associated with increased risk of ESBL-E colonisation, and protected water sources or water treatment by boiling may reduce risk. Conclusions: ESBL-E colonisation is common in sSA, but how people become carriers and why is not well understood. To inform the design of interventions to interrupt transmission in this setting requires longitudinal, community studies.https://wellcomeopenresearch.org/articles/4-160/v1
collection DOAJ
language English
format Article
sources DOAJ
author Joseph M. Lewis
Rebecca Lester
Paul Garner
Nicholas A. Feasey
spellingShingle Joseph M. Lewis
Rebecca Lester
Paul Garner
Nicholas A. Feasey
Gut mucosal colonisation with extended-spectrum beta-lactamase producing Enterobacteriaceae in sub-Saharan Africa: a systematic review and meta-analysis [version 1; peer review: 2 approved]
Wellcome Open Research
author_facet Joseph M. Lewis
Rebecca Lester
Paul Garner
Nicholas A. Feasey
author_sort Joseph M. Lewis
title Gut mucosal colonisation with extended-spectrum beta-lactamase producing Enterobacteriaceae in sub-Saharan Africa: a systematic review and meta-analysis [version 1; peer review: 2 approved]
title_short Gut mucosal colonisation with extended-spectrum beta-lactamase producing Enterobacteriaceae in sub-Saharan Africa: a systematic review and meta-analysis [version 1; peer review: 2 approved]
title_full Gut mucosal colonisation with extended-spectrum beta-lactamase producing Enterobacteriaceae in sub-Saharan Africa: a systematic review and meta-analysis [version 1; peer review: 2 approved]
title_fullStr Gut mucosal colonisation with extended-spectrum beta-lactamase producing Enterobacteriaceae in sub-Saharan Africa: a systematic review and meta-analysis [version 1; peer review: 2 approved]
title_full_unstemmed Gut mucosal colonisation with extended-spectrum beta-lactamase producing Enterobacteriaceae in sub-Saharan Africa: a systematic review and meta-analysis [version 1; peer review: 2 approved]
title_sort gut mucosal colonisation with extended-spectrum beta-lactamase producing enterobacteriaceae in sub-saharan africa: a systematic review and meta-analysis [version 1; peer review: 2 approved]
publisher Wellcome
series Wellcome Open Research
issn 2398-502X
publishDate 2019-10-01
description Background: Extended-spectrum beta-lactamase producing Enterobacteriaceae (ESBL-E) threaten human health; and, in areas of sub-Saharan Africa (sSA) where carbapenems are not available, may render ESBL-E infections untreatable. Gut mucosal colonisation probably occurs before infection, making prevention of colonisation an attractive target for intervention, but the epidemiology of ESBL-E in sSA is poorly described. Objectives: Describe ESBL-E colonisation prevalence in sSA and risk factors associated with colonisation. Methods: Studies included were prospective cross-sectional or cohort studies reporting gut mucosal ESBL-E colonisation in any population in sSA. We searched PubMed and Scopus on 18 December 2018. We summarise the range of prevalence across sites and tabulated risk factors for colonisation. The protocol was registered (Prospero ID CRD42019123559). Results: From 2975 abstracts we identified 32 studies including a total of 8619 participants from a range of countries and settings. Six studies were longitudinal; no longitudinal studies followed patients beyond hospital discharge.  Prevalence varied between 5 and 84% with a median of 31%, with a relationship to setting: pooled ESBL-E colonisation in community studies was 18% (95% CI 12 to 28, 12 studies); in studies recruiting people at admission to hospital colonisation was 32% (95% CI 24 to 41% 8 studies); and for inpatients, colonisation was 55% (95% CI 49 to 60%, 7 studies). Antimicrobial use was associated with increased risk of ESBL-E colonisation, and protected water sources or water treatment by boiling may reduce risk. Conclusions: ESBL-E colonisation is common in sSA, but how people become carriers and why is not well understood. To inform the design of interventions to interrupt transmission in this setting requires longitudinal, community studies.
url https://wellcomeopenresearch.org/articles/4-160/v1
work_keys_str_mv AT josephmlewis gutmucosalcolonisationwithextendedspectrumbetalactamaseproducingenterobacteriaceaeinsubsaharanafricaasystematicreviewandmetaanalysisversion1peerreview2approved
AT rebeccalester gutmucosalcolonisationwithextendedspectrumbetalactamaseproducingenterobacteriaceaeinsubsaharanafricaasystematicreviewandmetaanalysisversion1peerreview2approved
AT paulgarner gutmucosalcolonisationwithextendedspectrumbetalactamaseproducingenterobacteriaceaeinsubsaharanafricaasystematicreviewandmetaanalysisversion1peerreview2approved
AT nicholasafeasey gutmucosalcolonisationwithextendedspectrumbetalactamaseproducingenterobacteriaceaeinsubsaharanafricaasystematicreviewandmetaanalysisversion1peerreview2approved
_version_ 1724976367262498816